Related references
Note: Only part of the references are listed.Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine
Natasha M. DeVore et al.
FEBS JOURNAL (2012)
Peripheral Ligand-binding Site in Cytochrome P450 3A4 Located with Fluorescence Resonance Energy Transfer (FRET)
Dmitri R. Davydov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Three-dimensional Structure of Steroid 21-Hydroxylase (Cytochrome P450 21A2) with Two Substrates Reveals Locations of Disease-associated Variants
Bin Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Evaluation of Inhibition Selectivity for Human Cytochrome P450 2A Enzymes
Eva S. Stephens et al.
DRUG METABOLISM AND DISPOSITION (2012)
Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK
You Xu et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Human Cytochrome P450 2E1 Structures with Fatty Acid Analogs Reveal a Previously Unobserved Binding Mode
Patrick R. Porubsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Crystal Structures of Cytochrome P450 2B4 in Complex with the Inhibitor 1-Biphenyl-4-methyl-1H-imidazole: Ligand-Induced Structural Response through α-Helical Repositioning
Sean C. Gay et al.
BIOCHEMISTRY (2009)
Effect of CYP2A13 Active Site Mutation N297A on Metabolism of Coumarin and Tobacco-Specific Nitrosamines
Kari E. Schlicht et al.
DRUG METABOLISM AND DISPOSITION (2009)
Key Residues Controlling Binding of Diverse Ligands to Human Cytochrome P450 2A Enzymes
N. M. DeVore et al.
DRUG METABOLISM AND DISPOSITION (2009)
Key Residues Controlling Phenacetin Metabolism by Human Cytochrome P450 2A Enzymes
Natasha M. DeVore et al.
DRUG METABOLISM AND DISPOSITION (2008)
Determinants of cytochrome P4502C8 substrate binding -: Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid
Guillaume A. Schoch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Structures of Human Cytochrome P-450 2E1 INSIGHTS INTO THE BINDING OF INHIBITORS AND BOTH SMALL MOLECULAR WEIGHT AND FATTY ACID SUBSTRATES.
Patrick R. Porubsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice
Yan Weng et al.
CANCER RESEARCH (2007)
Structure of the human lung cytochrome P450 2A13
Brian D. Smith et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Functional characterization of CYP2A13 polymorphisms
K. E. Schlicht et al.
XENOBIOTICA (2007)
Synthetic inhibitors of cytochrome P-450 2A6: Inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization
Jason K. Yano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Structural basis for ligand promiscuity in cytochrome P450 3A4
Marika Ekroos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract
XY He et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Crystal structure of human cytochrome P450 2D6
P Rowland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism
LB von Weymarn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis
ZL Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen
JK Yano et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes
SE Murphy et al.
DRUG METABOLISM AND DISPOSITION (2005)
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence
V Malaiyandi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Metabolism and disposition kinetics of nicotine
J Hukkanen et al.
PHARMACOLOGICAL REVIEWS (2005)
Metabolism of nicotine and cotinine by human cytochrome P450 2A13
ZP Bao et al.
DRUG METABOLISM AND DISPOSITION (2005)
Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation
XY He et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2004)
Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen
XY He et al.
DRUG METABOLISM AND DISPOSITION (2004)
Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13
JR Jalas et al.
DRUG METABOLISM AND DISPOSITION (2003)
Characterization and mapping of DNA damage induced by reactive metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) at nucleotide resolution in human genomic DNA
JF Cloutier et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
2′-hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes:: Formation of a lung carcinogen precursor
SS Hecht et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
